About InVivoSIM anti-human C5 (Eculizumab Biosimilar) This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Eculizumab making it ideal for research use. This Eculizumab biosimilar reacts with human terminal complement component 5 (C5). C5 is a precursor protein synthesized in the liver. During complement activation, C5 is cleaved, producing two disulfide linked glycoproteins C5α and C5β. C5α is further cleaved by C5 convertase into C5a and C5α’, the latter binds to C5β to form C5b, which in turn sequentially recruits C6-C9 to form the membrane attack complex (MAC). MAC destroys pathogens by forming a lytic pore in their membrane. Eculizumab inhibits the cleavage of C5 to C5α and C5β. Eculizumab is used for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. InVivoSIM anti-human C5 (Eculizumab Biosimilar) Specifications IsotypeHuman IgG4 Recommended Isotype Control(s)RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman C5 Reported ApplicationsInhibition of the activation of C5 Functional assays ELISA Immunoprecipitation FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A RRIDAB_2894732 Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
